Overview

A Study of ZL-1310 Versus Investigator's Choice of Therapy in Participants With Relapsed Small Cell Lung Cancer

Status:
NOT_YET_RECRUITING

Trial end date:
2029-05-31

Target enrollment:

Participant gender:

Summary

The purpose of this study is to evaluate the efficacy and safety of ZL-1310 compared to Investigator's Choice Therapy in participants with relapsed Small Cell Lung Cancer.

Phase:

PHASE3

Details

Lead Sponsor:

Zai Lab (Shanghai) Co., Ltd.

Collaborator:

Zai Lab (US) LLC